UBS analyst Kevin Caliendo upgraded CVS Health (CVS) to Buy from Neutral with a price target of $79, up from $67. The company has posted to strong quarters of execution and early signs are emerging that its healthcare benefits segment fixes are on track, the analyst tells investors in a research note. UBS sees annual earnings growth of 14% through 2028 for CVS, above the consensus estimate of 12%. It sees a “compelling valuation” at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: